×
In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function.
Herrington WG., Zhu D., Haynes R.
DOI
10.7326/ACPJ201902190-015
Type
Other
Publication Date
19/02/2019
Volume
170